Phase 3 N=240 Pregabalin Peripheral Neuropathic Pain Study
Diabetic Neuropathies · Neuralgia
Primary: Daily Pain Rating Scale (DPRS)- Mean Pain Score (ITT Population) — 4.63; 5.13 score on scale — p=0.049
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=859 Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
Melanoma
Primary: Overall Survival — 9.13; 9.36 Months — p=0.9999
Phase 3 N=269 Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat
Pharyngitis
Primary: Sum of Sore Throat Pain Intensity Difference (SPID2) on Swallowing at 2 Hours Post-First Dose — 21.0; 9.4 units on a scale * hours — p=0.0003
Phase 3 N=1,670 A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
Acne Vulgaris
Primary: Success Rate on the Investigator's Global Assessment — 37.9; 21.8; 26.7; 17.9 Percentage of participants
Phase 3 N=107 Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)
Hepatitis C, Chronic
Primary: Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment — 70 Participants
Phase 3 N=39 Study of rhASB in Patients With Mucopolysaccharidosis VI
Mucopolysaccharidosis VI
Primary: 12-Minute Walk Test — 187; 118 meters
Phase 3 N=547 Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)
Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, Perennial
Primary: The Change From Baseline in the 12-hour AM/PM-PRIOR (Reflective) Total 5 Symptom Score (T5SS) From Subject Daily Diaries Averaged Over Treatment Days 1 to 15 — -3.01…
Phase 3 N=372 A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
Neuralgia, Postherpetic
Primary: Mean Pain Scores at Endpoint — 5.12; 4.81; 4.26; 4.49 score on scale — p=0.262
Phase 3 N=440 A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes
Bipolar Disorder
Primary: Number of Participants Who Had a Mood Relapse. — 42; 76; 98; 59 Participants — p=<0.001
Phase 3 N=443 Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease · Bronchitis · Emphysema
Primary: Percent (%) of Participants With Adverse Events (AEs), in Particular COPD Exacerbations — 66.7; 67.8; 76.2; 10.9 percent of participants
Phase 3 N=428 Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
Osteoporosis
Primary: Change From Baseline at 18 Month Endpoint in Lumbar Spine Bone Mineral Density (BMD) — 0.059; 0.028 grams per square centimeters — p=<0.001
Phase 3 N=3 Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease
Mucopolysaccharidosis I · Hurler Syndrome · Hurler-Scheie Syndrome
Primary: Safety Evaluation — 3; 0; 0; 1 participants
Phase 3 N=516 A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients
Overactive Bladder
Primary: Mean Number of Micturition Episodes Per 24 Hours — 12.7; 9.7 number of episodes — p=<0.0001
Phase 3 N=1,002 SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Stents · Coronary Artery Disease · Total Coronary Occlusion
Primary: Primary Endpoint: In-segment Late Loss (LL) — 0.14; 0.28 millimeters — p=<0.0001
Phase 3 N=276 Safety and Effectiveness Study of The Swedish Adjustable Gastric Band (SAGB) in the Treatment of Morbid Obesity
Obesity, Morbid
Primary: Percent of Subjects Who Had Adverse Events With the Swedish Adjustable Gastric Band (SAGB) — 69.6 Percent of Subjects